Loading
The breast screening AI tested in Sweden's MASAI trial, where AI-supported reading found more cancers and nearly halved the radiologists' workload.
Transpara (ScreenPoint Medical, Nijmegen) is CE-marked and FDA 510(k)-cleared for 2D mammography (2018) and digital breast tomosynthesis (2020). It was the software used in the MASAI randomised trial of 80,000 women in Sweden: the interim analysis (Lancet Oncology 2023) reported a cancer detection rate of 6.1 per 1,000 with AI-supported screening versus 5.1 per 1,000 with standard double reading, similar recall rates, and a 44.3% reduction in screen-reading workload. Transpara is deployed in screening programmes in Sweden, Denmark, Germany and elsewhere, and its use as one of two readers is the model the NHS is evaluating in the EDITH trial.
Deep-learning system scores each mammogram or tomosynthesis exam from 1 to 10 for cancer likelihood and marks suspicious regions, usable as a concurrent reader, second reader or triage tool.
1.Transpara slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| EU | 2017 | CE mark, mammography decision support |
| US | 2018 | 510(k) clearance, 2D mammography |
| US | 2020 | 510(k) clearance, digital breast tomosynthesis |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Transpara" OR ABSTRACT:"Transpara") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Transpara, not a curated reading list.
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares AI in radiology and the tag test.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.